oritavancin (BioDeep_00000009051)

   


代谢物信息卡片


Chlorobiphenyl-chloroeremomycin; LY333328; Oritavancin

化学式: C86H97Cl3N10O26 (1790.5641)
中文名称: 奥利万星
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1C(C(CC(O1)OC2C3C(=O)NC(C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)C(C(=O)N3)NC(=O)C6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)OC9C(C(C(C(O9)CO)O)O)OC1CC(C(C(O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)C(C(C(=O)NC(C(=O)N6)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O
InChI: InChI=1S/C86H97Cl3N10O26/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-/m0/s1

描述信息

A semisynthetic glycopeptide used (as its bisphosphate salt) for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms including MRSA.
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01X - Other antibacterials > J01XA - Glycopeptide antibacterials
C254 - Anti-Infective Agent > C258 - Antibiotic > C61101 - Glycopeptide Antibiotic
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents

同义名列表

5 个代谢物同义名

oritavancin; Chlorobiphenyl-chloroeremomycin; LY333328; Oritavancin; Chlorobiphenyl-chloroeremomycin; LY333328; Chlorobiphenyl-chloroeremomycin



数据库引用编号

13 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 4 ALB, CA2, DHFR, SPX
Peripheral membrane protein 1 CYP1B1
Endoplasmic reticulum membrane 1 CYP1B1
Nucleus 2 ALB, TGFBR1
cytosol 4 ALB, CA2, DHFR, PRKCQ
centrosome 1 ALB
Cell membrane 5 CA2, CCR9, CXCR6, IFNAR1, TGFBR1
Multi-pass membrane protein 3 CCR9, CXCR6, MRGPRX2
cell surface 3 CCR9, TGFBR1, TNR
glutamatergic synapse 1 TNR
Golgi apparatus 1 ALB
Golgi membrane 1 INS
mitochondrial inner membrane 1 LDHD
Cytoplasmic vesicle, secretory vesicle 1 SPX
Lysosome 1 IFNAR1
endosome 2 IFNAR1, TGFBR1
plasma membrane 12 CA2, CCR9, CXCR6, F2, IFNAR1, IFNAR2, IFNLR1, IGHE, IL10RB, MRGPRX2, PRKCQ, TGFBR1
Membrane 6 CYP1B1, IFNAR2, IFNLR1, IL10RB, MRGPRX2, TGFBR1
extracellular exosome 3 ALB, CA2, F2
endoplasmic reticulum 1 ALB
extracellular space 7 ALB, F2, IFNAR2, IGHE, INS, SPX, TNR
Schaffer collateral - CA1 synapse 1 TNR
Cell junction, tight junction 1 TGFBR1
bicellular tight junction 1 TGFBR1
mitochondrion 3 CYP1B1, DHFR, LDHD
protein-containing complex 1 ALB
intracellular membrane-bounded organelle 1 CYP1B1
Microsome membrane 1 CYP1B1
Single-pass type I membrane protein 5 IFNAR1, IFNAR2, IFNLR1, IGHE, TGFBR1
Secreted 3 ALB, F2, INS
extracellular region 7 ALB, F2, IFNAR2, IGHE, INS, SPX, TNR
anchoring junction 1 ALB
centriolar satellite 1 PRKCQ
external side of plasma membrane 2 CCR9, CXCR6
Secreted, extracellular space, extracellular matrix 1 TNR
apical part of cell 1 CA2
Membrane raft 2 TGFBR1, TNR
collagen-containing extracellular matrix 2 F2, TNR
Late endosome 1 IFNAR1
receptor complex 1 TGFBR1
ciliary basal body 1 ALB
IgE immunoglobulin complex 1 IGHE
centriole 1 ALB
Secreted, extracellular space 1 SPX
spindle pole 1 ALB
blood microparticle 2 ALB, F2
[Isoform 2]: Cell membrane 2 IFNAR2, IGHE
[Isoform 3]: Secreted 1 IFNAR2
endosome lumen 1 INS
myelin sheath 1 CA2
secretory granule lumen 1 INS
Golgi lumen 2 F2, INS
endoplasmic reticulum lumen 3 ALB, F2, INS
platelet alpha granule lumen 1 ALB
dense core granule 1 SPX
transport vesicle 2 INS, SPX
Endoplasmic reticulum-Golgi intermediate compartment membrane 1 INS
immunological synapse 1 PRKCQ
perineuronal net 1 TNR
aggresome 1 PRKCQ
[Isoform 1]: Cell membrane 2 IFNAR1, IFNAR2
[Isoform 3]: Cell membrane 1 IGHE
[Isoform 1]: Secreted 1 IGHE
IgE B cell receptor complex 1 IGHE
immunoglobulin complex, circulating 1 IGHE
tenascin complex 1 TNR
activin receptor complex 1 TGFBR1
transforming growth factor beta ligand-receptor complex 1 TGFBR1
ciliary transition fiber 1 ALB
interleukin-28 receptor complex 2 IFNLR1, IL10RB


文献列表

  • Suzannah M Schmidt-Malan, Kerryl E Greenwood-Quaintance, Lawrence J Berglund, Jayawant Mandrekar, Robin Patel. Oritavancin polymethylmethacrylate (PMMA)-compressive strength testing and in vitro elution. Journal of orthopaedic surgery and research. 2019 Feb; 14(1):43. doi: 10.1186/s13018-019-1080-6. [PMID: 30755223]
  • Ana Alejandra García Robles, Eduardo López Briz, María Dolores Fraga Fuentes, Rocío Asensi Diez, Jesús Francisco Sierra Sánchez. Review of oritavancin for the treatment of acute bacterial skin and skin structure infections. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2018 03; 42(2):73-81. doi: 10.7399/fh.10807. [PMID: 29501059]
  • Manmilan Singh, James Chang, Lauryn Coffman, Sung Joon Kim. Hidden Mode of Action of Glycopeptide Antibiotics: Inhibition of Wall Teichoic Acid Biosynthesis. The journal of physical chemistry. B. 2017 04; 121(16):3925-3932. doi: 10.1021/acs.jpcb.7b00324. [PMID: 28368603]
  • Debora Sweeney, Dean L Shinabarger, Francis F Arhin, Adam Belley, Greg Moeck, Chris M Pillar. Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Diagnostic microbiology and infectious disease. 2017 Feb; 87(2):121-128. doi: 10.1016/j.diagmicrobio.2016.11.002. [PMID: 27890418]
  • Adam Belley, Richard Robson, John L Francis, Dorothy M Adcock, Stefan Tiefenbacher, Christopher M Rubino, Greg Moeck, David Sylvester, Michael N Dudley, Jeffery Loutit. Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory. Antimicrobial agents and chemotherapy. 2017 02; 61(2):. doi: 10.1128/aac.01968-16. [PMID: 27956417]
  • Jay W Mason, S Eralp Bellibas, Nuo-Yu Huang, Carlos R Sanabria, Borje Darpo. Electrocardiographic Effects of a Supratherapeutic Dose of Oritavancin. Clinical pharmacology in drug development. 2016 Nov; 5(6):502-508. doi: 10.1002/cpdd.268. [PMID: 27138652]
  • Kenneth P Klinker, Samuel J Borgert. Beyond Vancomycin: The Tail of the Lipoglycopeptides. Clinical therapeutics. 2015 Dec; 37(12):2619-36. doi: 10.1016/j.clinthera.2015.11.007. [PMID: 26658277]
  • Daniela Münch, Ina Engels, Anna Müller, Katrin Reder-Christ, Hildegard Falkenstein-Paul, Gabriele Bierbaum, Fabian Grein, Gerd Bendas, Hans-Georg Sahl, Tanja Schneider. Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin. Antimicrobial agents and chemotherapy. 2015 Feb; 59(2):772-81. doi: 10.1128/aac.02663-14. [PMID: 25403671]
  • C M Rubino, S M Bhavnani, G Moeck, S E Bellibas, P G Ambrose. Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials. Antimicrobial agents and chemotherapy. 2015; 59(6):3365-72. doi: 10.1128/aac.00176-15. [PMID: 25824211]
  • Francis F Arhin, Ingrid Sarmiento, Gregory Moeck. In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene. International journal of antimicrobial agents. 2014 Jul; 44(1):65-8. doi: 10.1016/j.ijantimicag.2014.03.015. [PMID: 24906505]
  • Joseph W Ndieyira, Natascha Kappeler, Stephen Logan, Matthew A Cooper, Chris Abell, Rachel A McKendry, Gabriel Aeppli. Surface-stress sensors for rapid and ultrasensitive detection of active free drugs in human serum. Nature nanotechnology. 2014 Mar; 9(3):225-32. doi: 10.1038/nnano.2014.33. [PMID: 24584276]
  • Lamis R Karaoui, Rania El-Lababidi, Elias B Chahine. Oritavancin: an investigational lipoglycopeptide antibiotic. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2013 Jan; 70(1):23-33. doi: 10.2146/ajhp110572. [PMID: 23261897]
  • Jane Freeman, Miriam Marquis, Grace S Crowther, Sharie L Todhunter, Warren N Fawley, Caroline H Chilton, Gregory Moeck, Dario Lehoux, Mark H Wilcox. Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model. The Journal of antimicrobial chemotherapy. 2012 Dec; 67(12):2919-26. doi: 10.1093/jac/dks309. [PMID: 22899803]
  • C H Chilton, J Freeman, G S Crowther, S L Todhunter, M H Wilcox. Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model. The Journal of antimicrobial chemotherapy. 2012 Oct; 67(10):2434-7. doi: 10.1093/jac/dks243. [PMID: 22723601]
  • Beverlie Baquir, Sandrine Lemaire, Françoise Van Bambeke, Paul M Tulkens, Lin Lin, Brad Spellberg. Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2012 Apr; 54 Suppl 3(?):S229-32. doi: 10.1093/cid/cir921. [PMID: 22431853]
  • Atul Kumar, Henry J Mann, Mani Keshtgarpour, Michael A Flynn, Hong Deng, Adel Rafai Far, Thomas R Parr, Susan R Moriarty. In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers. The International journal of artificial organs. 2011 Nov; 34(11):1067-74. doi: 10.5301/ijao.5000008. [PMID: 22183520]
  • Oscar Domenech, Yves F Dufrêne, Françoise Van Bambeke, Paul M Tukens, Marie-Paule Mingeot-Leclercq. Interactions of oritavancin, a new semi-synthetic lipoglycopeptide, with lipids extracted from Staphylococcus aureus. Biochimica et biophysica acta. 2010 Oct; 1798(10):1876-85. doi: 10.1016/j.bbamem.2010.06.011. [PMID: 20599683]
  • Borje Darpo, Sun K Lee, Thomas E Moon, Nancy Sills, Jay W Mason. Oritavancin, a new lipoglycopeptide antibiotic: results from a thorough QT study. Journal of clinical pharmacology. 2010 Aug; 50(8):895-903. doi: 10.1177/0091270009355449. [PMID: 20484618]
  • Francis F Arhin, Adam Belley, Geoffrey McKay, Sylvain Beaulieu, Ingrid Sarmiento, Thomas R Parr, Gregory Moeck. Assessment of oritavancin serum protein binding across species. Antimicrobial agents and chemotherapy. 2010 Aug; 54(8):3481-3. doi: 10.1128/aac.00271-10. [PMID: 20498314]
  • Francis F Arhin, Geoffrey A McKay, Sylvain Beaulieu, Ingrid Sarmiento, Thomas R Parr, Gregory Moeck. Time-kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes. International journal of antimicrobial agents. 2009 Dec; 34(6):550-4. doi: 10.1016/j.ijantimicag.2009.08.012. [PMID: 19818587]
  • Christopher M Rubino, Scott A Van Wart, Sujata M Bhavnani, Paul G Ambrose, Jill S McCollam, Alan Forrest. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrobial agents and chemotherapy. 2009 Oct; 53(10):4422-8. doi: 10.1128/aac.00231-09. [PMID: 19635952]
  • Francis F Arhin, Geoffrey A McKay, Sylvain Beaulieu, Ingrid Sarmiento, Thomas R Parr, Gregory Moeck. Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus. Diagnostic microbiology and infectious disease. 2009 Oct; 65(2):207-10. doi: 10.1016/j.diagmicrobio.2009.05.022. [PMID: 19748436]
  • Oscar Domenech, Grégory Francius, Paul M Tulkens, Françoise Van Bambeke, Yves Dufrêne, Marie-Paule Mingeot-Leclercq. Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization. Biochimica et biophysica acta. 2009 Sep; 1788(9):1832-40. doi: 10.1016/j.bbamem.2009.05.003. [PMID: 19450541]
  • Sung Joon Kim, Manmilan Singh, Jacob Schaefer. Oritavancin binds to isolated protoplast membranes but not intact protoplasts of Staphylococcus aureus. Journal of molecular biology. 2009 Aug; 391(2):414-25. doi: 10.1016/j.jmb.2009.06.033. [PMID: 19538971]
  • Geoffrey A McKay, Sylvain Beaulieu, Francis F Arhin, Adam Belley, Ingrid Sarmiento, Thomas Parr, Gregory Moeck. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. The Journal of antimicrobial chemotherapy. 2009 Jun; 63(6):1191-9. doi: 10.1093/jac/dkp126. [PMID: 19369269]
  • Geoffrey A McKay, Sylvain Beaulieu, Ingrid Sarmiento, Francis F Arhin, Thomas R Parr, Gregory Moeck. Impact of human serum albumin on oritavancin in vitro activity against enterococci. Antimicrobial agents and chemotherapy. 2009 Jun; 53(6):2687-9. doi: 10.1128/aac.00197-09. [PMID: 19349514]
  • Françoise Van Bambeke, Jennifer Saffran, Marie-Paule Mingeot-Leclercq, Paul M Tulkens. Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation. Antimicrobial agents and chemotherapy. 2005 May; 49(5):1695-700. doi: 10.1128/aac.49.5.1695-1700.2005. [PMID: 15855483]
  • Gerald J Fetterly, Christine M Ong, Sujata M Bhavnani, Jeffrey S Loutit, Steven B Porter, Lisa G Morello, Paul G Ambrose, David P Nicolau. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrobial agents and chemotherapy. 2005 Jan; 49(1):148-52. doi: 10.1128/aac.49.1.148-152.2005. [PMID: 15616289]
  • Sujata M Bhavnani, Joel S Owen, Jeffery S Loutit, Steven B Porter, Paul G Ambrose. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagnostic microbiology and infectious disease. 2004 Oct; 50(2):95-102. doi: 10.1016/j.diagmicrobio.2004.06.007. [PMID: 15474317]
  • Françoise Van Bambeke, Stéphane Carryn, Cristina Seral, Hugues Chanteux, Donatienne Tyteca, Marie-Paule Mingeot-Leclercq, Paul M Tulkens. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrobial agents and chemotherapy. 2004 Aug; 48(8):2853-60. doi: 10.1128/aac.48.8.2853-2860.2004. [PMID: 15273091]
  • Cristina Seral, Françoise Van Bambeke, Paul M Tulkens. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrobial agents and chemotherapy. 2003 Jul; 47(7):2283-92. doi: 10.1128/aac.47.7.2283-2292.2003. [PMID: 12821480]
  • Carole J Boylan, Kristina Campanale, Philip W Iversen, Diane L Phillips, Michael L Zeckel, Thomas R Parr. Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrobial agents and chemotherapy. 2003 May; 47(5):1700-6. doi: 10.1128/aac.47.5.1700-1706.2003. [PMID: 12709343]
  • E A Coyle, M J Rybak. Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrobial agents and chemotherapy. 2001 Mar; 45(3):706-9. doi: 10.1128/aac.45.3.706-709.2001. [PMID: 11181347]
  • A Lefort, A Saleh-Mghir, L Garry, C Carbon, B Fantin. Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis. Antimicrobial agents and chemotherapy. 2000 Nov; 44(11):3017-21. doi: 10.1128/aac.44.11.3017-3021.2000. [PMID: 11036016]
  • A Saleh-Mghir, A Lefort, Y Petegnief, S Dautrey, J M Vallois, D Le Guludec, C Carbon, B Fantin. Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrobial agents and chemotherapy. 1999 Jan; 43(1):115-20. doi: 10.1128/aac.43.1.115. [PMID: 9869575]
  • A L Baltch, R P Smith, W J Ritz, L H Bopp. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium. Antimicrobial agents and chemotherapy. 1998 Oct; 42(10):2564-8. doi: 10.1128/aac.42.10.2564. [PMID: 9756756]
  • G G Zhanel, I D Kirkpatrick, D J Hoban, A M Kabani, J A Karlowsky. Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus. Antimicrobial agents and chemotherapy. 1998 Sep; 42(9):2427-30. doi: 10.1128/aac.42.9.2427. [PMID: 9736576]
  • G W Kaatz, S M Seo, J R Aeschlimann, H H Houlihan, R C Mercier, M J Rybak. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrobial agents and chemotherapy. 1998 Apr; 42(4):981-3. doi: 10.1128/aac.42.4.981. [PMID: 9559828]
  • F H van Tiel, T E van den Bogaard. In-vitro susceptibility to LY333328 of vancomycin-resistant enterococci isolated from humans and animals. The Journal of antimicrobial chemotherapy. 1997 Nov; 40(5):733-4. doi: 10.1093/jac/40.5.733. [PMID: 9421326]
  • R C Mercier, H H Houlihan, M J Rybak. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium. Antimicrobial agents and chemotherapy. 1997 Jun; 41(6):1307-12. doi: 10.1128/aac.41.6.1307. [PMID: 9174189]